These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36170667)

  • 1. Waning natural and vaccine-induced immunity leading to reinfection with SARS-CoV-2 Omicron variant.
    Shete AM; Patil DY; Sahay RR; Sapkal GN; Deshpande GR; Yadav PD
    Hum Vaccin Immunother; 2022 Nov; 18(6):2127289. PubMed ID: 36170667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
    Medigeshi GR; Batra G; Murugesan DR; Thiruvengadam R; Chattopadhyay S; Das B; Gosain M; Ayushi ; Singh J; Anbalagan A; Shaman H; Pargai K; Mehdi F; Das SJ; Kahlon N; Singh S; Kshetrapal P; Wadhwa N; Pandey AK; Bhatnagar S; Garg PK
    EBioMedicine; 2022 Apr; 78():103938. PubMed ID: 35305396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.
    Carazo S; Skowronski DM; Brisson M; Barkati S; Sauvageau C; Brousseau N; Gilca R; Fafard J; Talbot D; Ouakki M; Gilca V; Carignan A; Deceuninck G; De Wals P; De Serres G
    Lancet Infect Dis; 2023 Jan; 23(1):45-55. PubMed ID: 36152671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152.
    Yadav PD; Sardana V; Deshpande GR; Shinde PV; Thangaraj JWV; George LS; Sapkal GN; Patil DY; Sahay RR; Shete AM; Joshi M; Murhekar M; Godbole S; Gupta N; Prakash S; Rathore M; Ujjainiya R; Singh AP; Mishra A; Dash D; Chaudhary K; Sengupta S;
    Indian J Med Res; 2024 Feb; 159(2):223-231. PubMed ID: 38517215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022.
    Vicentini M; Venturelli F; Mancuso P; Bisaccia E; Zerbini A; Massari M; Cossarizza A; De Biasi S; Pezzotti P; Bedeschi E; Giorgi Rossi P; ;
    Euro Surveill; 2023 Mar; 28(13):. PubMed ID: 36995374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation.
    Gazit S; Saciuk Y; Perez G; Peretz A; Ben-Tov A; Stuart EA; Patalon T
    Lancet Microbe; 2023 Jul; 4(7):e495-e505. PubMed ID: 37062294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.
    Bobrovitz N; Ware H; Ma X; Li Z; Hosseini R; Cao C; Selemon A; Whelan M; Premji Z; Issa H; Cheng B; Abu Raddad LJ; Buckeridge DL; Van Kerkhove MD; Piechotta V; Higdon MM; Wilder-Smith A; Bergeri I; Feikin DR; Arora RK; Patel MK; Subissi L
    Lancet Infect Dis; 2023 May; 23(5):556-567. PubMed ID: 36681084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review.
    Arabi M; Al-Najjar Y; Sharma O; Kamal I; Javed A; Gohil HS; Paul P; Al-Khalifa AM; Laws S; Zakaria D
    BMC Infect Dis; 2023 Jun; 23(1):432. PubMed ID: 37365490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 immune response and reinfection in vaccinated Maya and mestizo in Southeast of Mexico.
    Monteón V; León-Pérez F; Ancona-León JG; Gutiérrez-Torres G
    Salud Publica Mex; 2023 Dec; 66(1, ene-feb):14-16. PubMed ID: 38065105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico.
    Montes-González JA; Zaragoza-Jiménez CA; Antonio-Villa NE; Fermín-Martínez CA; Ramírez-García D; Vargas-Vázquez A; Gutiérrez-Vargas RI; García-Rodríguez G; López-Gatell H; Valdés-Ferrer SI; Bello-Chavolla OY
    Front Public Health; 2023; 11():1146059. PubMed ID: 37081954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
    Shiwa-Sudo N; Sakai Y; Iwata-Yoshikawa N; Watanabe S; Yamada S; Kuroda Y; Yamamoto T; Shirakura M; Fujisaki S; Miyazaki K; Miura H; Nagata S; Fukushi S; Maeda K; Hasegawa H; Suzuki T; Nagata N
    J Virol; 2023 Jan; 97(1):e0136622. PubMed ID: 36633406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.
    Zheng H; Wu S; Chen W; Cai S; Zhan M; Chen C; Lin J; Xie Z; Ou J; Ye W
    Front Public Health; 2024; 12():1457266. PubMed ID: 39253287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals.
    Goh YS; Rouers A; Fong SW; Zhuo NZ; Hor PX; Loh CY; Huang Y; Neo VK; Kam IKJ; Wang B; Ngoh EZX; Salleh SNM; Lee RTC; Pada S; Sun LJ; Ong DLS; Somani J; Lee ES; ; ; Maurer-Stroh S; Wang CI; Leo YS; Ren EC; Lye DC; Young BE; Ng LFP; Renia L
    Front Immunol; 2022; 13():1031852. PubMed ID: 36451833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. History of primary-series and booster vaccination and protection against Omicron reinfection.
    Chemaitelly H; Ayoub HH; Tang P; Coyle PV; Yassine HM; Al Thani AA; Al-Khatib HA; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    Sci Adv; 2023 Oct; 9(40):eadh0761. PubMed ID: 37792951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of immune protection of SARS-CoV-2 natural infection against reinfection.
    Chemaitelly H; Nagelkerke N; Ayoub HH; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    J Travel Med; 2022 Dec; 29(8):. PubMed ID: 36179099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 reinfections with BA.1 (Omicron) variant among fully vaccinated individuals in northeastern Brazil.
    Freire-Neto FP; Teixeira DG; da Cunha DCS; Morais IC; Tavares CPM; Gurgel GP; Medeiros SDN; Santos DCD; Sales AO; Jeronimo SMB
    PLoS Negl Trop Dis; 2022 Oct; 16(10):e0010337. PubMed ID: 36191040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses.
    Torresi J; Edeling MA; Nolan T; Godfrey DI
    Front Immunol; 2022; 13():914167. PubMed ID: 35911696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection from infection and reinfection due to the Omicron BA.1 variant in care homes.
    Choudhry S; Rowland TAJ; McClelland K; Renz E; Iyanger N; Chow JY; Aiano F; Ladhani SN; Jeffery-Smith A; Andrews NJ; Zambon M
    Front Immunol; 2023; 14():1186134. PubMed ID: 37936695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 vaccine breakthrough reinfection in a health-care worker of Iraq: A case report.
    Hasan DA; Maulud SQ; Jalal PJ; Priyanka ; Choudhary OP
    Hum Vaccin Immunother; 2022 Nov; 18(5):2055947. PubMed ID: 35417318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia.
    Scutari R; Fox V; De Ioris MA; Fini V; Granaglia A; Costabile V; Colagrossi L; Russo C; Mastronuzzi A; Locatelli F; Perno CF; Alteri C
    BMC Infect Dis; 2023 Mar; 23(1):133. PubMed ID: 36882724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.